Skip to content
sellWeak cluster of 410b5-1 plan

Michael F Mahoney sold $17M of BSX

Chairman, President & CEO at BOSTON SCIENTIFIC CORP. 164,443 shares at an average of $103.69, traded Jun 2, 2025, filed Jun 3, 2025.

Warning score
35
Value
$17M
164,443 shares
Holdings after
1,476,882
-10% from before
From 52-week low
+26%
low $82.52, close $104.17
From 52-week high
-2%
high $106.66, as of Jun 2, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $17.1M at market
    +25
  • Share of holdings sold
    Sold 10% of holdings
    +5
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BSXOct 9, 2026 · close 42.73
Since filing Jun 3, 2025: -58.6%SPY +32.8% · excess -91.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001225208-25-005681, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 2, 2025MOption exercise
Common Stock10b5-1
+56,212$17.26$970k1,591,918Jun 3, 2025
Jun 2, 2025MOption exercise
Common Stock10b5-1
+49,407$24.55$1.2M1,641,325Jun 3, 2025
Jun 2, 2025SOpen-market sale
Common Stock10b5-1
-74,522$104.05$7.8M1,566,803Jun 3, 2025
Jun 2, 2025SOpen-market sale
Common Stock10b5-1
-89,921$103.39$9.3M1,476,882Jun 3, 2025
Jun 2, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-56,212$0.00$00Jun 3, 2025
Jun 2, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-49,407$0.00$0148,221Jun 3, 2025

Related signals

Other insiders at BOSTON SCIENTIFIC CORP and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
25Weak
BSXsell 410b5-1
BOSTON SCIENTIFIC CORP
Joseph Michael Fitzgerald
EVP & Group Pres, Cardiology
$5.8M
56,372 shares
-24%
51Moderate
BSXsell 4
BOSTON SCIENTIFIC CORP
Edward J Ludwig
director
$418k
4,000 shares
-15%
33Weak
BSXsell 410b5-1
BOSTON SCIENTIFIC CORP
Vance R Brown
SVP, GC and Corp. Secretary
$514k
4,826 shares
-13%
18Weak
BSXsell 410b5-1
BOSTON SCIENTIFIC CORP
John Bradley Sorenson
EVP, Global Operations
$478k
4,572 shares
-20%
40Moderate
BSXsell 410b5-1
BOSTON SCIENTIFIC CORP
Arthur C Butcher
EVP& Grp Pres, MedSurg & APAC
$1.8M
17,314 shares
-44%
30Weak
BSXsell 410b5-1
BOSTON SCIENTIFIC CORP
Michael F Mahoney
Chairman, President & CEO
$17M
164,443 shares
-10%
32Weak
BSXsell 410b5-1
BOSTON SCIENTIFIC CORP
Vance R Brown
SVP, GC and Corp. Secretary
$459k
4,826 shares
-12%
23Weak
BSXsell 210b5-1
BOSTON SCIENTIFIC CORP
Michael F Mahoney
Chairman, President & CEO
$16M
164,442 shares
-9%
26Weak
BSXsell 210b5-1
BOSTON SCIENTIFIC CORP
Vance R Brown
SVP, GC and Corp. Secretary
$487k
4,826 shares
-11%
37Weak
BSXsell 610b5-1
BOSTON SCIENTIFIC CORP
Emily Woodworth
SVP, Global Controller and CAO
$801k
7,631 shares
-95%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael F Mahoney sold $17M of BSX | InsiderTell